Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.
$475.7MCash on Hand
39.3mo Cash Runway
Follow JBIO by emailGet an email when JBIO reports key news in an SEC filing, pushes back a promised milestone, files for a stock offering, lands on the Downside Radar or has an FDA decision. Free, no account needed.
We send one confirmation email first. Only emails about JBIO, unsubscribe in one click. Privacy
📣 What JBIO Says Is Next
second quarter of 2027 · JADE101: “Enrollment in the Phase 2 JUNIPER trial of JADE101 in IgAN is ongoing, with interim data expected in the second quarter of 2027.”
Company press release, Nov 13, 2026 · SEC filing
fourth quarter of 2026 · JADE101: “Jade expects to initiate EVERGREEN, a Phase 3 registrational trial of JADE101 in IgAN, in the fourth quarter of 2026, reflecting the Company’s rapid execution as JADE101 advances into registrational development.”
Company press release, Nov 13, 2026 · SEC filing
fourth quarter of 2026 · “JADE301 Phase 1 clinical trial in dermatomyositis expected to initiate in the fourth quarter of 2026, with interim data expected in the second half of 2027”
Company press release, Nov 13, 2026 · SEC filing
Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.
📄 Latest SEC Filings in Plain English
Nov 13, 2026 ·
Quarterly report for the period ended Sep 30, 2026 Form 10-Q · SEC filing
Nov 13, 2026 ·
Earnings Reported Q3 2026 net loss of $35.1 million, up from $25.2 million, with R&D expenses of $30.8 million and G&A of $8.8 million. Cash and investments were $475.7 million, funding operations into Q4 2028. Phase 3 EVERGREEN trial of JADE101 expected to start Q4 2026. Form 8-K · SEC filing · Press release
Sep 30, 2026 ·
Clinical trial Announced preclinical data for JADE301, an anti-IFN-ß antibody for dermatomyositis, showing an 11.3 pM binding affinity and an approximately 30-day half-life in primates. Plans a placebo-controlled Phase 1 trial in 24 healthy volunteers in Q4 2026, with interim data expected in H2 2027. Form 8-K · SEC filing
Aug 10, 2026 ·
Earnings Reported Q2 2026 results: cash, equivalents and investments of $461.2 million, with runway into Q4 2028. Net loss was $55.8 million versus $32.1 million a year earlier. Announced positive interim Phase 1 JADE101 data and a Phase 1 start for JADE301 in Q4 2026. Form 8-K · SEC filing · Press release
Aug 10, 2026 ·
Quarterly report for the period ended Jun 30, 2026 Form 10-Q · SEC filing
Each summary is written by AI from the filing itself, and one that names a number or a name the filing does not contain is not shown. Quarterly and annual reports are listed by period. Read the filing before acting on it.
🧪 Trial & FDA Catalysts
May 2027 · Phase 1 · Recruiting · A Single Dose, Phase 1 Study of JADE101 in Healthy Japanese and Chinese Participants Registry primary completion date, not a results date
Oct 2027 · Phase 1 · Recruiting · A Phase 1 Study of JADE201 in Participants With Rheumatoid Arthritis Registry primary completion date, not a results date
Jan 2029 · Phase 2 · Recruiting · A Study of JADE101 in Participants With Immunoglobulin A Nephropathy Registry primary completion date, not a results date
Jun 2029 · Phase 3 · Recruiting · A Phase 3 Blinded Study of JADE101 in Participants With Immunoglobulin A Nephropathy Registry primary completion date, not a results date
Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it
💰 Cash Runway & Dilution Risk
JBIO holds $475.7M in cash and short-term investments (as of Sep 30, 2026) and burns about $36.3M/quarter from operations,
an estimated runway of 39.3 months at that rate (BioRadar estimate, not company guidance).
Share count 69,189,448 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the total held by all 13F filers (Yahoo Finance); the table lists the largest. Sources have different dates, so the split is approximate. Source: SEC EDGAR.
Get the full JBIO picture
The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for JBIO and every other ticker you follow. Card required, cancel anytime.
Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z
This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.